Trials / Withdrawn
WithdrawnNCT00386555
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Phase 2 Study of CP-868,596 + Docetaxel, AG-013736 + Docetaxel, or CP-868,596 + AG-013736 + Docetaxel and of Docetaxel Alone in Patients With Stage IIIb or IV Non-Small Cell Lung Cancer.
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Arog Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | docetaxel | |
| DRUG | CP-868,596 + docetaxel | |
| DRUG | AG-013736 + docetaxel | |
| DRUG | CP-868,596 + AG-013736 + docetaxel |
Timeline
- Start date
- 2007-05-01
- First posted
- 2006-10-11
- Last updated
- 2012-08-09
Source: ClinicalTrials.gov record NCT00386555. Inclusion in this directory is not an endorsement.